Literature DB >> 15507440

A unique hydrophobic cluster near the active site contributes to differences in borrelidin inhibition among threonyl-tRNA synthetases.

Benfang Ruan1, Michael L Bovee, Meik Sacher, Constantinos Stathopoulos, Karl Poralla, Christopher S Francklyn, Dieter Söll.   

Abstract

Borrelidin, a compound with anti-microbial and anti-angiogenic properties, is a known inhibitor of bacterial and eukaryal threonyl-tRNA synthetase (ThrRS). The inhibition mechanism of borrelidin is not well understood. Archaea contain archaeal and bacterial genre ThrRS enzymes that can be distinguished by their sequence. We explored species-specific borrelidin inhibition of ThrRSs. The activity of ThrRS from Sulfolobus solfataricus and Halobacterium sp. NRC-1 was inhibited by borrelidin, whereas ThrRS enzymes from Methanocaldococcus jannaschii and Archaeoglobus fulgidus were not. In Escherichia coli ThrRS, borrelidin binding induced a conformational change, and threonine was not activated as shown by ATP-PP(i) exchange and a transient kinetic assay measuring intrinsic tryptophan fluorescence changes. These assays further showed that borrelidin is a noncompetitive tight binding inhibitor of E. coli ThrRS with respect to threonine and ATP. Genetic selection of borrelidin-resistant mutants showed that borrelidin binds to a hydrophobic region (Thr-307, His-309, Cys-334, Pro-335, Leu-489, Leu-493) proximal to the zinc ion at the active site of the E. coli ThrRS. Mutating residue Leu-489 --> Trp reduced the space of the hydrophobic cluster and resulted in a 1500-fold increase of the K(i) value from 4 nM to 6 microm. An alignment of ThrRS sequences showed that this cluster is conserved in most organisms except for some Archaea (e.g. M. jannaschii, A. fulgidus) and some pathogens (e.g. Helicobacter pylori). This study illustrates how one class of natural product inhibitors affects aminoacyl-tRNA synthetase function, providing potentially useful information for structure-based inhibitor design.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507440     DOI: 10.1074/jbc.M411039200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents.

Authors:  Julian Gregston Hurdle; Alexander John O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Misacylation of specific nonmethionyl tRNAs by a bacterial methionyl-tRNA synthetase.

Authors:  Thomas E Jones; Rebecca W Alexander; Tao Pan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

3.  Genetic validation of aminoacyl-tRNA synthetases as drug targets in Trypanosoma brucei.

Authors:  Savitha Kalidas; Igor Cestari; Severine Monnerat; Qiong Li; Sandesh Regmi; Nicholas Hasle; Mehdi Labaied; Marilyn Parsons; Kenneth Stuart; Margaret A Phillips
Journal:  Eukaryot Cell       Date:  2014-02-21

4.  The tRNA A76 Hydroxyl Groups Control Partitioning of the tRNA-dependent Pre- and Post-transfer Editing Pathways in Class I tRNA Synthetase.

Authors:  Nevena Cvetesic; Mirna Bilus; Ita Gruic-Sovulj
Journal:  J Biol Chem       Date:  2015-04-14       Impact factor: 5.157

Review 5.  Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics.

Authors:  Christopher S Francklyn; Patrick Mullen
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

Review 6.  Characterization of aminoacyl-tRNA synthetase stability and substrate interaction by differential scanning fluorimetry.

Authors:  Jamie A Abbott; Nathan M Livingston; Shawn B Egri; Ethan Guth; Christopher S Francklyn
Journal:  Methods       Date:  2016-10-26       Impact factor: 3.608

7.  Aminoacyl-tRNA synthetase inhibition activates a pathway that branches from the canonical amino acid response in mammalian cells.

Authors:  Yeonjin Kim; Mark S Sundrud; Changqian Zhou; Maja Edenius; Davide Zocco; Kristen Powers; Miao Zhang; Ralph Mazitschek; Anjana Rao; Chang-Yeol Yeo; Erika H Noss; Michael B Brenner; Malcolm Whitman; Tracy L Keller
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-06       Impact factor: 11.205

8.  Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo.

Authors:  Eva Maria Novoa; Noelia Camacho; Anna Tor; Barrie Wilkinson; Steven Moss; Patricia Marín-García; Isabel G Azcárate; José M Bautista; Adam C Mirando; Christopher S Francklyn; Sònia Varon; Miriam Royo; Alfred Cortés; Lluís Ribas de Pouplana
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

9.  Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis.

Authors:  Carola Huthmacher; Andreas Hoppe; Sascha Bulik; Hermann-Georg Holzhütter
Journal:  BMC Syst Biol       Date:  2010-08-31

10.  Crystal structure of the aspartyl-tRNA synthetase from Entamoeba histolytica.

Authors:  Ethan A Merritt; Tracy L Arakaki; Eric T Larson; Angela Kelley; Natascha Mueller; Alberto J Napuli; Li Zhang; George Deditta; Joseph Luft; Christophe L M J Verlinde; Erkang Fan; Frank Zucker; Frederick S Buckner; Wesley C Van Voorhis; Wim G J Hol
Journal:  Mol Biochem Parasitol       Date:  2009-10-27       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.